Amgen Inc.

NASDAQ Global Select
Back to all articles
Bullish +65

Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?

AI-generated analysis

📈 Amgen reported a 20% relative risk reduction in all-cause mortality for high-risk adults treated with Repatha in the VESALIUS-CV trial.

💉 The study enrolled over 12,000 patients and followed them for a median of 4.6 years to assess long-term outcomes.

🫀 Repatha reduced the risk of coronary heart disease death, myocardial infarction, or ischemic stroke by 25% in the trial population.

📉 LDL-C levels reached a median of 45 mg/dL at 48 weeks with Repatha compared to 109 mg/dL for placebo.

🏥 The FDA broadened Repatha's U.S. indication in 2025 for adults at increased risk of major cardiovascular events due to uncontrolled LDL-C.

🇪🇺 The European Commission expanded Repatha's indication in August 2026 based on the VESALIUS-CV trial results.

📊 Approximately 9 million patients have received Repatha globally across 51 clinical trials over the last 15 years.

💰 Amgen may not need a new patient population for growth but must overcome adoption barriers related to reimbursement and prescribing behavior.

💉 Repatha is an injectable drug, which presents a practical barrier compared to lower-cost oral treatments like statins and ezetimibe.

📉 The mortality benefit was a prespecified secondary analysis, not the trial's primary endpoint, requiring careful interpretation of absolute vs. relative risk.

👥 66 hedge funds held Amgen Inc. at the end of Q2 2026, up from 65 funds three months earlier.

📈 The evidence supports using Repatha earlier in treatment for high-risk patients with uncontrolled LDL-C despite standard therapy.

Bullish Signals
  • Amgen reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial.
  • The study enrolled more than 12,000 high-risk adults and followed them for a median of 4.6 years, showing the mortality benefit began after approximately 1.5 years.
  • Repatha reduced the risk of coronary heart disease death, myocardial infarction, or ischemic stroke by 25% in the trial population.
  • The drug lowered the risk of a broader cardiovascular composite by 19% and reduced the risk of myocardial infarction by 36%.
  • In a lipid substudy, median LDL-C at 48 weeks reached 45 mg/dL with Repatha compared to 109 mg/dL for placebo.
  • The FDA broadened Repatha's U.S. indication in 2025 to adults at increased risk of major cardiovascular events because of uncontrolled LDL-C.
  • The European Commission expanded its indication in August 2026 based on the VESALIUS-CV trial results.
  • Repatha has been studied for 15 years across 51 clinical trials involving more than 57,000 patients, with approximately 9 million patients receiving the drug globally.
Risk Factors
  • The reported 20% mortality figure is a relative risk reduction, and Amgen did not provide absolute mortality event rates in the announcement.
  • The enrolled patients were carefully selected to have established atherosclerotic disease or high-risk diabetes, limiting broad generalizability to everyone with elevated cholesterol.
  • Repatha is an injectable drug, while statins and ezetimibe are lower-cost oral treatments, creating a practical barrier to adoption.
  • Payer restrictions can slow access to Repatha, potentially hindering the translation of clinical evidence into market growth.
  • The effect of the new mortality evidence on patient persistence remains unproven.
Full Analysis
Amgen Inc. (NASDAQ: AMGN) reported significant findings from a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial, indicating that its PCSK9 inhibitor, Repatha, reduced the risk of all-cause mortality by 20% in high-risk adults without prior heart attacks or strokes. The study, which followed over 12,000 patients for a median of 4.6 years, showed that this mortality benefit began to appear after approximately 1.5 years of treatment. Beyond the mortality data, Repatha demonstrated robust efficacy in reducing major cardiovascular events, lowering the risk of coronary heart disease death, myocardial infarction, or ischemic stroke by 25%. The drug also significantly reduced the risk of a broader cardiovascular composite by 19% and lowered LDL-C levels to 45 mg/dL at 48 weeks compared to 109 mg/dL for placebo. These results reinforce the drug's value in patients with uncontrolled LDL-C despite standard therapy. The commercial implications of these findings center on expanding Repatha's use earlier in treatment protocols, potentially before a patient's first major cardiovascular event. With the FDA having broadened the U.S. indication in 2025 and the European Commission expanding it in August 2026 based on VESALIUS-CV data, Amgen now faces the challenge of translating stronger mortality evidence into broader guideline adoption, payer reimbursement, and physician prescribing confidence to realize market growth. Despite the positive clinical data, practical barriers remain, including Repatha's injectable nature versus lower-cost oral alternatives like statins and ezetimibe. The article notes that while the evidence improves the case for earlier use, the ultimate market expansion will depend on absolute benefit realization, reimbursement access, and patient willingness to adopt an injectable regimen over established oral therapies.